{rfName}
Fi

Indexed in

Citations

16

Altmetrics

Analysis of institutional authors

Barrio PCorresponding AuthorTeixidor LAuthorOrtega LAuthorRico NAuthorVieta EAuthorGual AAuthor

Share

January 8, 2018
Publications
>
Article
No

Filling the gap between lab and clinical impact: An open randomized diagnostic trial comparing urinary ethylglucuronide and ethanol in alcohol dependent outpatients

Publicated to: DRUG AND ALCOHOL DEPENDENCE. 183 (183): 225-230 - 2018-02-01 183(183), DOI: 10.1016/j.drugalcdep.2017.11.015

Authors:

Barrio, Pablo; Teixidor, Lidia; Ortega, Lluisa; Lligona, Anna; Rico, Nayra; Luis Bedini, Jose; Vieta, Eduard; Gual, Antoni
[+]

Affiliations

Clin Hosp, Clin Neurosci Inst, Addict Behav Unit, Villarroel 170, Barcelona 08036, Spain - Author
Ctr Invest Red Salud Mental CIBERSAM, Pabellon 11, Madrid 28029, Spain      CIBERSAM    CIBER - Centro de Investigacion Biomedica en Red - Author
Hosp Clin Barcelona, Dept Biochem, Barcelona, Spain      Hospital Clinic de Barcelona    University of Barcelona - Author
Hosp Clin Barcelona, Villarroel 170, E-08036 Barcelona, Spain.      University of Barcelona    Hospital Clinic de Barcelona - Author
Univ Barcelona, Dept Psychiat & Clin Psychobiol, Casanova 143, E-08036 Barcelona, Spain      University of Barcelona - Author
Univ Barcelona, Hosp Clin Barcelona, Red Trastornos Adict RETICS, Grp Recerca Addicc Clin,IDIBAPS, Villarroel 170, E-08036 Barcelona, Spain      University of Barcelona    IDIBAPS    Hospital Clinic de Barcelona - Author
Univ Barcelona, Hosp Clin, Inst Neurosci, Bipolar Disorder Program,IDIBAPS, Villarroel 170, E-08036 Barcelona, Spain      IDIBAPS    Hospital Clinic de Barcelona    University of Barcelona - Author
       - Author
See more

Abstract

Efforts aimed at reducing alcohol-related harm include early detection of risky drinkers as well as detection of early relapse in patients with alcohol dependence. Ethyl glucuronide (EtG) has been proven to be a reliable biomarker for the detection of recent drinking; however, no randomized, diagnostic trial to date has tested its impact on drinking outcomes. The aim of this study was to assess, in a randomized design, the implications of EtG screening on alcohol outcomes, compared to screening with a low sensitivity biomarker such as ethanol.Alcohol dependent outpatients were randomized to either 24 weeks of continuous screening with EtG or ethanol. Patients were aware of screening methods and results. After 24 weeks, all participants were screened with EtG. Self-reports were also gathered. A logistic regression compared the rate of EtG positive results at study end between groups. Generalized estimating equations evaluated the descending monthly rate of EtG positive patients in the EtG group.A total of 162 patients were randomized. During the study period, the ethanol group showed less patients with positive screens (19/64 (29.7%) vs 58/98 (59%)). After 24 weeks, the EtG group showed a greater number of patients having a negative screening test compared to ethanol subjects when they were all screened with EtG (5/62 (8.1%) vs 13/39 (33.3%)). A significant decrease in the rate of EtG positive patients was found for the first three months of the study.Routine screening with EtG seems to reduce drinking and improve abstinence rates in alcohol dependent outpatients.Copyright © 2017 Elsevier B.V. All rights reserved.
[+]

Keywords

abusealcohol dependenceconsumptiondiseaseethyl glucuroniderandomized diagnostic trialsensitivityspecificitysubstance usesulfateurine screeninguse disordersvalidityAdultAlcohol dependenceAlcohol drinkingAlcoholismBiomarkersEthanolEthyl glucuronideFemaleGlucuronatesHumansMaleMiddle agedOutpatientsRandomized diagnostic trialSubstance abuse detectionUrine screening

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal DRUG AND ALCOHOL DEPENDENCE due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2018, it was in position 4/19, thus managing to position itself as a Q1 (Primer Cuartil), in the category Substance Abuse.

Independientemente del impacto esperado determinado por el canal de difusión, es importante destacar el impacto real observado de la propia aportación.

Según las diferentes agencias de indexación, el número de citas acumuladas por esta publicación hasta la fecha 2026-04-11:

  • WoS: 4
  • Scopus: 3
  • Europe PMC: 4
[+]

Impact and social visibility

From the perspective of influence or social adoption, and based on metrics associated with mentions and interactions provided by agencies specializing in calculating the so-called "Alternative or Social Metrics," we can highlight as of 2026-04-11:

  • The use, from an academic perspective evidenced by the Altmetric agency indicator referring to aggregations made by the personal bibliographic manager Mendeley, gives us a total of: 39.
  • The use of this contribution in bookmarks, code forks, additions to favorite lists for recurrent reading, as well as general views, indicates that someone is using the publication as a basis for their current work. This may be a notable indicator of future more formal and academic citations. This claim is supported by the result of the "Capture" indicator, which yields a total of: 39 (PlumX).

With a more dissemination-oriented intent and targeting more general audiences, we can observe other more global scores such as:

  • The Total Score from Altmetric: 1.
  • The number of mentions on the social network Facebook: 1 (Altmetric).
[+]

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: First Author (Barrio Giménez, Pablo) and Last Author (Gual Solé, Antoni).

the author responsible for correspondence tasks has been Barrio Giménez, Pablo.

[+]